Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. Jude Medical’s single-connector lead is approved

This article was originally published in The Gray Sheet

Executive Summary

FDA approves the first "four-pole" defibrillator connector system, allowing a single connection between a cardiac resynchronization therapy defibrillator (CRT-D) and its leads with one set screw, St. Jude announces Feb. 5. Traditional lead designs require three connections and four set screws. The new connector, known as IS-4 and also being developed by Medtronic and Boston Scientific, is meant to simplify surgical placement and provide a smaller product. St. Jude's "SJ4" system uses a Durata defibrillation lead and Promote CRT-D with SJ4 connectors. The firm will conduct a five-year post-approval study with up to 1,700 patients and gather additional data through its SCORE patient registry. Critics have called for greater pre-market human testing of such innovative lead designs for the sake of patient safety (1"The Gray Sheet" Dec. 15, 2008, p. 7)


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts